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Abstract 
Soluble TNF-like weak inducer of apoptosis (sTWEAK) is a member of the TNF 
superfamily whose concentrations have been related with the presence of 
chronic kidney disease (CKD) and cardiovascular disease (CVD). We 
hypothesized that sTWEAK levels may relate to atherosclerotic burden (defined 
as the number of atherosclerotic plaques) and atheromatosis progression 
(defined as an increment in the number of atherosclerotic plaques). For that 
purpose, we have analyzed baseline sTWEAK serum concentrations in seven 
hundred CKD patients without any previous CV event from the NEFRONA 
Study, and their association with atherosclerotic burden and atheromatosis 
progression after 24 months of follow-up. 
A continuous decrease in sTWEAK concentrations with an increase in the 
number of atherosclerotic plaques after 24 moths of follow-up was observed in 
the studied population. Multivariable linear regression analysis showed that 
age, blood pressure, HDL-c, and sTWEAK concentrations were independent 
predictors of atherosclerotic burden after 24 months of follow-up. In addition, 
sTWEAK concentrations were diminished in CKD patients in whom 
atheromatosis progression was observed. After adjustment for confounders, 
the odds ratio for atheromatosis progression in patients in the lowest versus the 
highest tertile of sTWEAK was 1.76 [95% confidence interval, 1.19-2.63; 
p=0.003]. 
In conclusion, lower sTWEAK concentrations at baseline are associated with 
atherosclerotic burden and atheromatosis progression in CKD patients free 
from clinical CVD. These data suggest that sTWEAK could serve as a 
biomarker to predict CV risk before clinical manifestations. 
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Cardiovascular disease (CVD) is the main cause of death in patients with 
chronic kidney disease (CKD), in which cardiovascular death is the main 
outcome 1. Compared to the CVD mortality in the general population, the rate 
of deaths in CKD is 15 to ?? times higher than in non-CKD subjects 2. The 
mechanisms for elevated CVD risk in CKD patients are very complex and may 
implicate changes in the vasculature. In this sense, it has been shown that 
increases in plaque burden have a strong predictive value assessing 
cardiovascular events in the general population 3, and the existence of 
accelerated atheromatosis in CKD population could play an important role in 
their higher cardiovascular mortality. However, little is known about the 
predictors of atheromatosis progression in patients with CKD.  
Atherosclerosis is a multifactorial disease characterized by a chronic 
inflammatory response and excessive cell proliferation. Several cytokines 
contribute to atherosclerotic plaque development participating as inflammatory 
messengers 4. One of these proinflammatory cytokines is tumor necrosis factor-
like weak inducer of apoptosis (TWEAK). TWEAK, a member of the TNF 
superfamily, participates in several responses associated with atherosclerotic 
plaque development such as inflammation, proliferation, angiogenesis, matrix 
degeneration and thrombosis 5. Different experimental studies have 
demonstrated that TWEAK, through is receptor Fn14, plays a key role in 
atherosclerotic plaque development, progression and subsequent rupture 6-8. 
In addition, gain or loss-of function experiments have demonstrated that 
TWEAK participates in the development of experimental stroke, abdominal 
aortic aneurysm, heart failure and myocardial infarction 9-12. 
TWEAK is expressed as a full-length, membrane-bound protein and then 
is proteolytically processed by furin, leading to the release of a 156-amino acid, 
18 kDa soluble form (sTWEAK) 13. sTWEAK was described as a potential 
biomarker being detected in lower amount in the secretome from carotid 
atherosclerotic plaques than in healthy walls 14. Since then, the association of 
sTWEAK with CVD or CVD-related diseases has been extensively studied. 
sTWEAK concentrations are diminished in patients with coronary artery 
disease 15, type II diabetes 16, systolic heart failure 17, abdominal aortic 
aneurysm 18, and CKD 19. However, the impact of circulating sTWEAK 
concentration on atheromatosis progression is unknown. 
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The National Observatory of Atherosclerosis in Nephrology (NEFRONA) 
Study was an observational multicenter prospective study designed to evaluate 
the prevalence and evolution of subclinical atheromatosis in CKD patients 20. 
The NEFRONA Study has shown that patients in early CKD stages already 
have a higher prevalence of atherosclerotic plaques than those without CKD 21. 
In addition, atheromatosis progression affects more than one half of the 
patients included in the NEFRONA study 22. In this study, we analyzed the 
association between sTWEAK and atheromatosis progression in the 
NEFRONA population. 
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Results 
Characteristics of the CKD population 
Seven hundred CKD patients free from clinical CVD [age 62 (52-68) 
years; median (IQR); 61% men] were included in the study. Of patients, 68% 
have dyslipidemia, 93% have hypertension, 28% were diabetic, and 58% 
smokers. The demographic and clinical characteristics of the studied population 
according to CKD stages are summarized in Table 1. There were significant 
differences among the different CKD stages regarding age, gender, body mass 
index, presence of dyslipidemia, and sTWEAK concentrations.  
Baseline circulating levels of sTWEAK in the overall population was 409 
(271-580) pg/mL. No differences in sTWEAK concentrations were observed in 
CKD patients with diabetes, hypertension or dyslipidemia compared with those 
without these cardiovascular risk factors. Current smokers (N=410) presented 
lower sTWEAK concentrations compared with non-smokers (N=292) [390 (262-
562) vs 442 (288-599) pg/mL; median (IQR); p=0.019]. No differences were 
found according to the prescription of anti-hypertensive drugs, statins or anti-
diabetic treatments. 
Atheromatous plaque prevalence at baseline was 67.5% without 
significant differences between CKD stages. Patients with atherosclerotic 
plaques showed lower sTWEAK concentrations compared with those without 
plaques [375 (262-537) vs 505 (319-652) pg/mL; median (IQR); p<0.001]. 
 
sTWEAK and atheromatosis progression  
We found a weak but significant correlation between baseline sTWEAK 
levels and c-IMT and ABI at 24 months (r=-0.102, p=0.008; and r=0.096, 
p=0.011; respectively). Furthermore, patients with severe atherosclerosis at 24 
months showed reduced baseline sTWEAK levels as compared with the 
incipient atherosclerosis group [373 (262-537) vs 503 (340-646) pg/mL; median 
(IQR); p<0.001; Fig. 1A]. To clarify the link between sTWEAK and severity of 
atherosclerosis, we have analyzed baseline sTWEAK concentrations according 
with the number of territories with atherosclerotic plaques (10 territories 
studied). Baseline sTWEAK levels were reduced with increasing number of 
atherosclerotic plaques. Thus, subjects with 1-4 or ≥5 territories with plaques 
showed lower baseline sTWEAK concentrations compared with those without 
 5 
plaques at 24 months (Fig. 1B). In addition, CKD patients with multiple 
territories affected (≥5) also presented lower sTWEAK levels than CKD patients 
with 1-4 territories with atherosclerotic plaques (Fig. 1B). To confirm that 
baseline sTWEAK could be a biomarker of atherosclerotic burden at 24 months 
of follow-up, a multivariable linear regression analysis was performed with the 
number of atherosclerotic plaques at 24 months as a dependent variable (Table 
2). Age, SBP, DBP, HDL-c and sTWEAK concentrations were independent 
predictors of atherosclerotic burden at 24 months of follow-up (r=0.389). 
In order to analyze the potential association between baseline sTWEAK 
concentrations and atheromatosis progression, CKD patients were divided in 
two groups: no atheromatosis progression (patients without increased number 
of atherosclerotic plaques at 24 months); and atheromatosis progression 
(appearance of new plaque/s at 24 months). The percentage of patients with 
atherosclerotic plaque/s increased from 67.5% to 80.5% at 24 months. 
Atheromatosis progression occurred in 58.4% of patients. Baseline potential 
factors predicting atheromatosis progression are summarized in Table 3. There 
were significant differences among patients with progression and no 
progression regarding age, gender, glucose concentrations, and the presence 
of hypertension, diabetes and/or dyslipidemia.  
Table 4 shows univariate regression logistic analysis to assess predictors 
of atheromatosis progression in CKD patients. Low sTWEAK concentrations 
were defined as sTWEAK levels below the 33rd percentile (≤ 309 pg/mL) and 
high sTWEAK as its concentrations above 66th percentile (≥ 517 pg/mL). In 
univariate analysis, older age, gender, current smokers, presence of 
hypertension, diabetes and/or dyslipidemia, use of anti-diabetic drugs, and 
lowest sTWEAK tertile were predictors of atheromatosis progression. After that, 
multivariable logistic regression analysis including only variables that were 
statistically significant in the univariate analysis was performed to assess 
predictors of atheromatosis progression. Older age, current smoker, and lowest 
sTWEAK tertile were independent predictors of atheromatosis progression. 
 
  
Discussion 
 6 
In this work, we investigated sTWEAK serum levels as predictors of 
atheromatosis progression after 24 months of follow-up in a CKD population 
with or without cardiovascular risk factors but free from previous clinical CVD. 
We have observed that patients with severe atherosclerosis at 24 months 
showed lower sTWEAK concentrations compared with those with incipient 
atherosclerosis. In addition, we have observed that sTWEAK levels were 
associated with atherosclerotic burden after 24 months of follow-up. Finally, we 
observed for the first time an independent and significant association between 
low sTWEAK concentration and atheromatosis progression in CKD patients. 
According to previous data in which low sTWEAK levels have been 
observed in patients with carotid atherosclerosis and CAD, we also showed that 
sTWEAK concentrations are reduced in CKD patients with atherosclerosis. 
Moreover, sTWEAK levels were even more reduced in CKD patients with 
severe atherosclerosis compared with those with incipient atherosclerosis. In 
this sense, sTWEAK concentrations have been related to different surrogate 
markers of atherosclerosis namely carotid intima/media thickness and 
endothelial dysfunction 14, 19, 23-26. Thus, sTWEAK levels have been negatively 
associated with c-IMT in CKD or asymptomatic patients 14, 23-26. However, this 
association was not confirmed in other cohorts and, indeed, positively 
association has been shown in transplanted CKD patients 27, which could be 
due to the presence of special therapy regimens used before and after renal 
transplantation. In addition, sTWEAK concentrations are strongly and 
independently correlated with flow-mediated dilation, suggesting a link between 
endothelial dysfunction and sTWEAK in CKD patients 19. We have also 
observed a continuous decrease in sTWEAK concentrations with an increase 
in the number of atherosclerotic plaques after 24 moths of follow-up in the 
studied population. This is in agreement with previous data obtained from 
asymptomatic patients in which sTWEAK levels were related with the amount 
of atherosclerotic plaques 26. Overall, these data indicate that sTWEAK could 
be a biomarker of atherosclerotic burden and severity in CKD patients. 
Traditional cardiovascular risk factors are associated with the presence of 
atherosclerotic plaques and burden. However, few studies have analyzed the 
predictors of atheromatosis progression over time 28-29. Atheromatosis 
progression has been recently analyzed in the NEFRONA Study after 24 
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months of follow-up, observing a high prevalence of atheromatosis progression 
in CKD patients 30. In our sub-population, older age and current smoker were 
predictors of atheromatosis progression. This is according with data obtained 
from the MESA Study in which current smokers was also a strong predictor of 
new plaque formation 31. More interestingly, our study also indicates that 
baseline sTWEAK concentrations may predict atheromatosis progression 
measured by increased number of territories with plaques in CKD patients. 
The reasons by which the progression of atherosclerosis is associated 
with sTWEAK levels are unknown, but experimental evidence suggests a 
causal role. TWEAK is expressed in both the normal and pathological arterial 
wall, but Fn14 is almost absent in healthy arteries and its expression is highly 
upregulated in the carotid and femoral atherosclerotic plaques 33-34. Binding of 
TWEAK to its receptor induces several responses in vascular and inflammatory 
cells. Thus, TWEAK increases adhesion molecules and proinflammatory 
cytokines expression in vascular cells and infiltrating macrophages, 
upregulates metaloproteinases activity and participates in prothrombotic 
responses and vascular calcification 5. Experiments from animal models have 
demonstrated that TWEAK participates in development, progression and 
rupture of atherosclerotic plaques. Systemic injection of TWEAK increased 
atherosclerotic plaque size and inflammatory response in the aortic root of 
ApoE deficient mice 8. In addition, genetic deletion of TWEAK reduced plaque 
progression and increased plaque stability in ApoE deficient mice 7. Data from 
experimental models support that TWEAK and its functional receptor Fn14 are 
a promising target for the treatment of patients with different CVD. Treatment 
with the TWEAK neutralizing antibody or Fn14-Fc decoy protein has 
demonstrated a beneficial effect on the development and progression of 
atherosclerotic plaques in mice 6-7. 
The mechanism(s) by which sTWEAK is reduced in CKD patients with 
atherosclerosis are unknown. The increment in Fn14 expression observed in 
pathological arterial wall could favor sTWEAK binding and retention in tissue. 
In addition, the presence of CD163, a scavenger receptor of TWEAK, in 
pathological tissues could facilitate TWEAK degradation by inflammatory 
macrophages, leading to low TWEAK levels 34. In this sense, it has been 
reported that both sTWEAK and CD163 are expressed in an opposite trend in 
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human carotid atherosclerotic plaques 35. However, this is a hypothesis that 
needs to be tested in further studies. 
Strengths of this study are the relatively large sample size of CKD patients 
with longitudinal observations included in our study. In addition, this population 
included CKD patients from daily clinical practice with or without concomitant 
medication with the aim to have a representative population. Moreover, 
vascular exploration was done by the same team and evaluated by a single 
reader. However, some limitations of our study should be highlighted for a 
correct interpretation of the implications of our findings. There is an intentional 
bias, because only patients with no history of cardiovascular events were 
included, as the study was aimed to primary prevention of cardiovascular 
events. In addition, plaque volume and density was not measured. 
In conclusion, our study shows that baseline sTWEAK concentrations 
could be an independent predictor for the development of atherosclerotic 
plaques in CKD patients.  
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Methods 
Patients 
Studied population included 700 patients (CKD 3-5 and dialysis) from the 
observational and multicenter NEFRONA study, recruited from October 2009 
to June 2011 20-21 and with 24 moths of follow-up. The NEFRONA study 
included male and female without history of CVD (angina pectoris, acute 
myocardial infarction, ischemic stroke, hemorrhagic stroke, abdominal aortic 
aneurysm and atherosclerosis), and ages ranged between 18 and 74 years old 
if they had CKD stage 3 or higher as defined by current guidelines (eGFR lower 
than 60 mL/min/1.73 m2 estimated using the 4-variable Modification of Diet in 
Renal Disease (MDRD) equation]. Exclusion criteria were pregnancy, VIH 
infection, any type of organ transplantation, previous history of carotid artery 
disease, active infections, any hospitalization in the last month, and intercurrent 
illness that presumes absence of follow-up or survival expectation less than 1 
year. The exclusion criteria were previous CV events, active infections (HIV, 
tuberculosis), pregnancy, having received any organ transplantation, and 
having a life expectancy of <1 year. For the prospective study at 24 months, 
renal parameters serum creatinine and eGFR), carotid/femoral echography, 
atheromatous disease (AD), ankle-brachial index (ABI), intima-media thickness 
(IMT), CV events and mortality were assessed. 
Each local ethics committee approved the study. The authors adhered to 
the declaration of Helsinki and patients were included after providing informed 
consent. 
 
Clinical and biochemical data 
At recruitment, the patients were asked to complete a questionnaire 
including clinical history of diabetes, hypertension and dyslipidemia; CV risk 
factors and medication use. 
The itinerant teams collected the anthropometric parameters and blood 
samples. Blood samples were processed immediately after extraction and 
storage at -20º C. After that, samples were sent and stored at -80º C within 24h 
at the centralized biobank of the Spanish Network for Nephrological Research. 
Biochemical parameters were obtained from a routine fasting blood test. Serum 
sTWEAK concentrations were determined in duplicate with commercially 
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available ELISA kits (Bender MedSystems, Vienna, Austria). The same 
investigator measured all samples in a blinded manner (IIS-Fundación Jiménez 
Díaz). The minimum detectable level of sTWEAK was 10 pg/ml. Intra- and 
interassay coefficients of variation were 7.3 and 8.5%, respectively. 
Atherosclerosis diagnosis 
Subclinical atherosclerosis was evaluated as described previously 20. 
Participants underwent a carotid and femoral ultra- sound to measure IMT, 
using the Vivid BT09 apparatus (General Electric instrument) equipped with a 
6e13 MHz broadband linear array probe. The analysis of the presence of 
atheromatous plaques was performed by a unique reader in a blinded fashion, 
using the semi-automatic software EchoPAC Dimension (General Electric 
Healthcare). To assess the quality of the reading and the intra-observer 
reliability, a sample of 20 individuals was measured 3-5 times on different days. 
A kappa coefficient of 1 was obtained, indicating excellent intraobserver 
reliability. 
Plaque presence was evaluated in a total of 10 territories: right common 
carotid arteries, right carotid bulb, right internal carotid arteries, left common 
carotid arteries, left carotid bulb, left internal carotid arteries, right common 
femoral arteries, right superficial femoral arteries, left common femoral arteries, 
and left superficial femoral arteries. Atheromatosis progression was defined as 
an increase in the number of territories showing a plaque with respect to the 
baseline visit as previously used in the Multi-Ethnic Study of Atherosclerosis 
(MESA) Study 31. Patients were also classified in three groups according to the 
number of territories with plaques at 24 months: 0; 1 to 4; and ≥5.  
Atherosclerotic disease (AD) was initially classified in four groups: AD 0: 
ABI >0.9 and IMT <80% reference interval; AD 1: ABI 0.7-0.9 and/or IMT ≥80% 
reference interval; AD 2: carotid plaque with stenosis <125 cm/s; and AD3: ABI 
<0.7 and/or carotid plaque with stenosis ≥125 cm/s 20-22. For this study, AD was 
classified in two groups, incipient AD (combining AD 0 and 1) and severe AD 
(combining AD 2 and 3), as previously reported 36. 
Statistical Analyses 
All of the statistical analyses were performed using the SPSS 11.0 (SPSS, 
Chicago, IL) statistical package. Non-normally distributed variables were 
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expressed as median (IQR, expressed as the 25th and 75th), and normally 
distributed variables were expressed as mean±SD. Between-group 
comparisons were assessed for nominal variables with the X2 test and by 
Mann-Whitney U or Kruskal-Wallis test. Multiple linear regression analyses 
using the number of territories with atherosclerotic plaques at 24 months as 
dependent variable was performed to identify independent predictor of 
atherosclerotic burden. Ninety-five percent confidence intervals (CI) were 
calculated for each comparison. p-value <0.05 was considered statistically 
significant. 
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Figure Legends 
Figure 1: sTWEAK concentrations, atherosclerotic burden and atheromatosis 
progression in CKD patients. 
A) Box plots showing the difference in baseline sTWEAK levels [median (IQR)] 
according to the stage of AD at 24 months of follow-up. Incipient AD (AD 0-1), 
N=218; Severe AD (AD 2-3), N=484.  
B) Box plots showing the difference in baseline sTWEAK levels [median (IQR)] 
according to the number of atherosclerotic plaques at 24 months of follow-up. 
No plaques, N=137; 1-4 plaques, N=341; >5 plaques; N=224.  
C) Box plots showing the difference in baseline sTWEAK levels [median (IQR)] 
according to atheromatosis progression at 24 months of follow-up. No 
progression, N=291; Progression, N=411.  
Whiskers represent 10th and 90th percentiles.  
